Last reviewed · How we verify
Aurora kinase inhibitor AT9283
At a glance
| Generic name | Aurora kinase inhibitor AT9283 |
|---|---|
| Sponsor | NCIC Clinical Trials Group |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias (PHASE1, PHASE2)
- Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (PHASE1)
- AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors (PHASE1)
- AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |